CIRCULATING TUMOR DNA (CTDNA) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-151724 |   Service

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Circulating Tumor Dna (Ctdna) Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL CIRCULATING TUMOR DNA (CTDNA) MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CIRCULATING TUMOR DNA (CTDNA) MARKET

7.1 GLOBAL CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Vermillion, Inc

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 FOUNDATION MEDICINE, INC

16.3 Biocept, Inc

16.4 Myriad Genetics, Inc

16.5 OncoCyte

16.6 Veracyte, Inc

16.7 GUARDANT HEALTH, INC

16.8 RainDance Technologies, Inc

16.9 QIAGEN

16.10 Adaptive Biotechnology

16.11 Trovagene

16.12 SAGA Diagnostics AB

16.13 Inivata Ltd

16.14 Abnova Corporation

16.15 iCellate AB

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type
Blood
Urine
Others

By Application
Routine Screening
Patient Work Up
Early-Stage Disease
Late Stage/Metastatic Disease

Companies

Vermillion, Inc
FOUNDATION MEDICINE, INC
Biocept, Inc
Myriad Genetics, Inc
OncoCyte
Veracyte, Inc
GUARDANT HEALTH, INC
RainDance Technologies, Inc
QIAGEN
Adaptive Biotechnology
Trovagene
SAGA Diagnostics AB
Inivata Ltd
Abnova Corporation
iCellate AB

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.